CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±èÀº°æ
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : ¸¸¼ºÆó¼â¼ºÆóÁúȯ, Æó°áÇÙ, °£Áú¼ºÆóÁúȯ, Æó¾Ï
  • Á÷ À§: ºÎ±³¼ö
  • ¸Þ ÀÏ:
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
28 (±¹³»)SCOPUS °´Ç÷ ȯÀÚ¿¡¼­ ±â°üÁö°æ¼úÀ̳ª ±â°üÁöµ¿¸Æ»öÀü¼ú ½ÃÇà ÀüÀÇ ´ÙÁß ÀýÆí Àü»êÈ­´ÜÃþÃÔ¿µÀÇ À¯¿ë¼º
27 (±¹¿Ü)SCIE Rosiglitazone attenuates hypoxia-induced pulmonary arterial hypertension in rats
26 (±¹¿Ü)SCI Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype
25 (±¹³»)KCI ¸¸¼ºÆó¼â¼ºÆóÁúȯ ±Þ¼º ¾ÇÈ­·Î ÀÔ¿øÇÑ È¯ÀÚÀÇ ¼¼±Õ¼º ¿øÀÎ
24 (±¹¿Ü)SCIE Prostatic metastasis of large cell neuroendocrine carcinoma of the lung
23 (±¹¿Ü)SCI Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis
22 (±¹¿Ü)SCIE Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD
21 (±¹¿Ü)SCI CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease
20 (±¹¿Ü)SCI Lung Function Response to 12-week Treatment with Combined Inhalation of Long-acting ¥â2 Agonist and Glucocorticoid According to ADRB2 Polymorphism in Patients with Chronic Obstructive Pulmonary Disease
19 (±¹¿Ü)SCI Bronchobiliary fistula treated with histoacryl embolization under bronchoscopic guidance
ÀÌÀüÆäÀÌÁö À̵¿ 11 12 13 14 15 16 17 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729